Literature DB >> 6329525

Adoptive transfer of experimental allergic encephalomyelitis in mice with the aid of pertussigen from Bordetella pertussis.

J J Munoz, I R Mackay.   

Abstract

Adoptive transfer of experimental allergic encephalomyelitis (EAE) in (SJL X BALB/c)F1 mice was accomplished by an iv injection of 2.4 to 4.7 X 10(7) lymph node cells (LNC) from mice immunized with mouse spinal cord emulsified in complete Freund's adjuvant when both donors and recipients had been treated iv with 400 ng of pertussigen at the time of immunization for the donors and on transfer of cells for the recipients. Pertussigen was essential in both donors and recipients for development of frank EAE. Signs of EAE in recipients were delayed, appearing 21-23 days after cell transfer; the maximum response at about Day 27 is considerably delayed in comparison with other reported studies on passive transfer of EAE. Histologically, recipient mice with paralysis due to EAE had typical perivascular infiltrates of mononuclear cells in the brain and spinal cord. The mechanisms by which pertussigen promotes the development of EAE after adoptive transfer of sensitized LNC are uncertain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329525     DOI: 10.1016/0008-8749(84)90410-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  Dual effects of pertussis toxin on in vitro invasive behavior of metastatic lymphoma variants.

Authors:  H Verschueren; D Van Hecke; E Hannecart-Pokorni; D Dekegel; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1989 Sep-Oct       Impact factor: 5.150

2.  Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model.

Authors:  Jun-xiang Yin; Jiang-long Tu; Hao-jie Lin; Fu-dong Shi; Ru-lan Liu; Chong-bo Zhao; Stephen W Coons; Sandra Kuniyoshi; Jiong Shi
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.